Publications by authors named "K Takaura"
The enhanced liver fibrosis (ELF) score is a blood test that combines three markers linked to liver fibrosis. The utility of the ELF score has been demonstrated primarily in Western countries, but whether it is useful in areas with a high number of elderly people suffering from chronic liver disease has yet to be determined. This is a prospective study that included 373 consecutive patients who underwent a liver biopsy and had their ELF score measured on the same day.
View Article and Find Full Text PDFBackground And Aim: Magnetic resonance elastography (MRE) is used for the evaluation of liver fibrosis; however, it remains unclear whether MRE-based liver stiffness is associated with hepatocellular carcinoma (HCC) development, particularly in patients with chronic hepatitis B.
Methods: A total of 504 patients with chronic hepatitis B receiving MRE were enrolled. The was the association between MRE-based liver stiffness and HCC.
Background And Aim: Immune checkpoint inhibitors pose the risk of immune-related adverse events (irAEs). Recent data suggest that irAEs may be associated with a favorable prognosis. This study aimed to investigate and analyze the association between these adverse events and the clinical benefits in patients with unresectable hepatocellular carcinoma.
View Article and Find Full Text PDFAim: A multisociety consensus group proposed a new nomenclature for metabolic dysfunction-associated steatotic liver disease (MASLD). Although patients with nonalcoholic fatty liver disease (NAFLD) are expected to be reclassified as patients with MASLD under the new nomenclature, the concordance between MASLD and NAFLD remains unclear. Moreover, waist circumference could be adjusted by ethnicity for diagnosing MASLD; however, there are limited data on the optimal waist circumference in the Japanese population.
View Article and Find Full Text PDFArticle Synopsis
- The use of anti-CD20 based immunochemotherapy has improved outcomes for patients with B-cell non-Hodgkin lymphoma (B-NHL), but relapsed or refractory cases still pose treatment challenges.
- Epcoritamab is a bispecific antibody that targets both T cells and B cells, effectively inducing cell death in B-cell lymphomas and was shown to have consistent efficacy in various preclinical models.
- Clinical trials confirmed the safety and effectiveness of epcoritamab, leading to its approval in Japan in September 2023 for treating specific types of relapsed or refractory B-NHL.